197 related articles for article (PubMed ID: 33771903)
1. Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with
Strosberg JR; Srirajaskanthan R; El-Haddad G; Wolin EM; Chasen BR; Kulke MH; Bushnell DL; Caplin ME; Baum RP; Hendifar AE; Öberg K; Ruszniewski P; Santoro P; Broberg P; Leeuwenkamp OR; Krenning EP
J Nucl Med; 2021 Mar; 62(12):1712-8. PubMed ID: 33771903
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of Lutetium [
Leeuwenkamp O; Smith-Palmer J; Ortiz R; Werner A; Valentine W; Blachier M; Walter T
J Med Econ; 2020 Dec; 23(12):1534-1541. PubMed ID: 32990484
[TBL] [Abstract][Full Text] [Related]
3. Phase 3 Trial of
Strosberg J; El-Haddad G; Wolin E; Hendifar A; Yao J; Chasen B; Mittra E; Kunz PL; Kulke MH; Jacene H; Bushnell D; O'Dorisio TM; Baum RP; Kulkarni HR; Caplin M; Lebtahi R; Hobday T; Delpassand E; Van Cutsem E; Benson A; Srirajaskanthan R; Pavel M; Mora J; Berlin J; Grande E; Reed N; Seregni E; Öberg K; Lopera Sierra M; Santoro P; Thevenet T; Erion JL; Ruszniewski P; Kwekkeboom D; Krenning E;
N Engl J Med; 2017 Jan; 376(2):125-135. PubMed ID: 28076709
[TBL] [Abstract][Full Text] [Related]
4.
Strosberg JR; Caplin ME; Kunz PL; Ruszniewski PB; Bodei L; Hendifar A; Mittra E; Wolin EM; Yao JC; Pavel ME; Grande E; Van Cutsem E; Seregni E; Duarte H; Gericke G; Bartalotta A; Mariani MF; Demange A; Mutevelic S; Krenning EP;
Lancet Oncol; 2021 Dec; 22(12):1752-1763. PubMed ID: 34793718
[TBL] [Abstract][Full Text] [Related]
5.
Satapathy S; Mittal BR; Sood A; Sood A; Kapoor R; Gupta R; Khosla D
JCO Glob Oncol; 2021 Jul; 7():1167-1175. PubMed ID: 34288699
[TBL] [Abstract][Full Text] [Related]
6. Lutetium oxodotreotide (
Smith-Palmer J; Leeuwenkamp OR; Virk J; Reed N
BMC Cancer; 2021 Jan; 21(1):10. PubMed ID: 33402120
[TBL] [Abstract][Full Text] [Related]
7. Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with
Strosberg J; Kunz PL; Hendifar A; Yao J; Bushnell D; Kulke MH; Baum RP; Caplin M; Ruszniewski P; Delpassand E; Hobday T; Verslype C; Benson A; Srirajaskanthan R; Pavel M; Mora J; Berlin J; Grande E; Reed N; Seregni E; Paganelli G; Severi S; Morse M; Metz DC; Ansquer C; Courbon F; Al-Nahhas A; Baudin E; Giammarile F; Taïeb D; Mittra E; Wolin E; O'Dorisio TM; Lebtahi R; Deroose CM; Grana CM; Bodei L; Öberg K; Polack BD; He B; Mariani MF; Gericke G; Santoro P; Erion JL; Ravasi L; Krenning E;
Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2372-2382. PubMed ID: 32123969
[TBL] [Abstract][Full Text] [Related]
8. Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With
Strosberg J; Wolin E; Chasen B; Kulke M; Bushnell D; Caplin M; Baum RP; Kunz P; Hobday T; Hendifar A; Oberg K; Sierra ML; Thevenet T; Margalet I; Ruszniewski P; Krenning E;
J Clin Oncol; 2018 Sep; 36(25):2578-2584. PubMed ID: 29878866
[TBL] [Abstract][Full Text] [Related]
9. The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?
Harris PE; Zhernosekov K
Front Endocrinol (Lausanne); 2022; 13():941832. PubMed ID: 36387893
[TBL] [Abstract][Full Text] [Related]
10. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M
Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002
[TBL] [Abstract][Full Text] [Related]
11. Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR.
Huynh L; Totev T; Vekeman F; Neary MP; Duh MS; Benson AB
J Med Econ; 2017 Sep; 20(9):945-951. PubMed ID: 28562131
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of peptide receptor radionuclide therapy with
Kobayashi N; Takano S; Ito K; Sugiura M; Ogawa M; Takeda Y; Okubo N; Suzuki A; Tokuhisa M; Kaneta T; Utsunomiya D; Hata M; Inoue T; Hosono M; Kinuya S; Ichikawa Y
Ann Nucl Med; 2021 Dec; 35(12):1332-1341. PubMed ID: 34533700
[TBL] [Abstract][Full Text] [Related]
13. Radionuclide Therapy for Neuroendocrine Tumors.
Cives M; Strosberg J
Curr Oncol Rep; 2017 Feb; 19(2):9. PubMed ID: 28220446
[TBL] [Abstract][Full Text] [Related]
14. Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors.
Nicolini S; Bodei L; Bongiovanni A; Sansovini M; Grassi I; Ibrahim T; Monti M; Caroli P; Sarnelli A; Diano D; Di Iorio V; Grana CM; Cittanti C; Pieri F; Severi S; Paganelli G
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3260-3267. PubMed ID: 33604690
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcome of indigenous
Sitani K; Parghane RV; Talole S; Basu S
Br J Radiol; 2021 Jan; 94(1117):20201041. PubMed ID: 33095671
[TBL] [Abstract][Full Text] [Related]
16. Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review.
Broder MS; Beenhouwer D; Strosberg JR; Neary MP; Cherepanov D
World J Gastroenterol; 2015 Feb; 21(6):1945-55. PubMed ID: 25684964
[TBL] [Abstract][Full Text] [Related]
17. Neuroendocrine Tumor Therapy:
Mittra ES
AJR Am J Roentgenol; 2018 Aug; 211(2):278-285. PubMed ID: 29949416
[TBL] [Abstract][Full Text] [Related]
18. ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy.
Love C; Desai NB; Abraham T; Banks KP; Bodei L; Boike T; Brown RKJ; Bushnell DL; DeBlanche LE; Dominello MM; Francis T; Grady EC; Hobbs RF; Hope TA; Kempf JS; Pryma DA; Rule W; Savir-Baruch B; Sethi I; Subramaniam RM; Xiao Y; Schechter NR
Clin Nucl Med; 2022 Jun; 47(6):503-511. PubMed ID: 35507433
[TBL] [Abstract][Full Text] [Related]
19. PLGA nanoparticles for peptide receptor radionuclide therapy of neuroendocrine tumors: a novel approach towards reduction of renal radiation dose.
Arora G; Shukla J; Ghosh S; Maulik SK; Malhotra A; Bandopadhyaya G
PLoS One; 2012; 7(3):e34019. PubMed ID: 22442740
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of lutetium (
Palmer J; Leeuwenkamp OR
World J Clin Cases; 2020 Oct; 8(20):4793-4806. PubMed ID: 33195647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
